WAM
EBAC

Wolverine Asset Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Wolverine Asset Management’s Portfolio EBAC Stock Details EBAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-499
Closed -$4K – 2371
2021
Q3 		$4K Buy
+499
New +$4.83K ﹤0.01% 1880

Other funds holding EBAC

HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wolverine Asset Management's EBAC Position: Q4 2021 in Review

Wolverine Asset Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q4 2021, closing a stake of 499 shares — an estimated $4K sold.

Wolverine Asset Management first reported a position in EBAC in Q3 2021 and held it in 1 quarter. The position peaked at $4K in Q3 2021. 45 funds tracked by Wall St. Rank hold EBAC as of Q4 2021.

  • Wolverine Asset Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q4 2021 after selling out during the quarter.
  • Wolverine Asset Management sold 499 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q4 2021, an estimated $4K.
  • Wolverine Asset Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q3 2021 and held it in 1 quarter.
  • Wolverine Asset Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $4K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q4 2021.

Based on Wolverine Asset Management's 13F filing for Q4 2021, filed 9 Feb 2022.